PRAGMA Therapeutics is a pharmaceutical biotech company focused in the discovery and development of small molecule therapeutics for post-traumatic stress disorders and hearing loss.
PRAGMA Therapeutics
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://pragmatherapeutics.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address92 Rue Ada Byron, 74160ArchampsFrance
92 Rue Ada Byron, 74160
Archamps
France
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/pragma-therapeutics” connections=”true” suffix=””]
PRAGMA is developing several, proprietary drug-like molecules acting at mGlu7 receptor, proven to play a major role in the regulation of glutamatergic neurotransmission in specific brain areas. mGlu7 has demonstrated to be involved in the regulation of traumatic memories, emotion and fear-related behaviours.
In April 2016, PRAGMA Therapeutics was awarded £300,000 from UK charity Action on Hearing Loss to develop new drugs to treat Hearing Loss. Also, Pragma is a member of Lyonbiopole which provides company the inital funding.